Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25/− mouse model of autosomal dominant polycystic kidney disease
- 89 Downloads
Increased levels of cyclooxygenase (COX) derived oxylipins is the earliest and most consistent alteration in the renal oxylipin profile in diverse models of cystic kidney diseases. Therefore, we examined whether a COX2 inhibitor would reduce disease progression in the Pkd2WS25/− mouse model of autosomal dominant polycystic kidney disease (ADPKD).
Weanling normal and diseased male Pkd2 mice were provided diets that provided 0 or 50 mg celecoxib/kg body weight/day, for 13 weeks. Renal disease and function were assessed by histomorphometric analysis of renal cysts and measurement of serum creatinine and urea nitrogen (SUN) levels. Targeted lipidomic analysis of renal oxylipins was performed by HPLC–MS/MS.
Diseased mice had significant cyst involvement and reduced renal function as indicated by elevated serum creatinine and SUN. Celecoxib reduced cyst area by 48%, cyst volume by 70%, and serum creatinine and SUN by 20% and 16%, respectively. Consistent with our previous studies, 8 of the 11 COX derived oxylipins were higher in diseased kidneys. In addition, 24 of 33 lipoxygenase (LOX) derived oxylipins and 7 of 16 cytochrome P450 (CYP) derived oxylipins were lower in diseased kidneys. Celecoxib reduced total and five of the eight individual elevated COX oxylipins and increased 5 of 24 LOX and 5 of 7 CYP oxylipins that were reduced by disease.
COX2 inhibition ameliorates disease progression, improves renal function and improves the altered oxylipins in Pkd2 mice. This represents a potential new approach for treatment of ADPKD, a disorder for which no effective treatment currently exists.
KeywordsAutosomal dominant polycystic kidney disease (ADPKD) Celecoxib Cyclooxygenase (COX) Cyst Oxylipin
We gratefully acknowledge T. Winter for her technical assistance.
This study was supported by a Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) (RGPIN-2015-03733) to HMA. Research studentship support was from the University of Manitoba Graduate Fellowship, Queen Elizabeth II Diamond Jubilee Scholarship, Janet Fabro McComb Scholarship and GETS Scholarship programs to MM.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of University of Manitoba.
- 2.Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND (2015) Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs Context 4:212275Google Scholar
- 6.Yamaguchi T, Devassy JG, Gabbs M, Ravandi A, Nagao S, Aukema HM (2015) Dietary flax oil rich in alpha-linolenic acid reduces renal disease and oxylipin abnormalities, including formation of docosahexaenoic acid derived oxylipins in the CD1-pcy/pcy mouse model of nephronophthisis. Prostaglandins Leukot Essent Fatty Acids 94:83–89CrossRefGoogle Scholar
- 24.Ibrahim NH, Gregoire M, Devassy JG, Wu Y, Yoshihara D, Yamaguchi T, Nagao S, Aukema HM (2015) Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease. Prostaglandins Other Lipid Mediat 116–117:19–25CrossRefGoogle Scholar
- 51.Warth LC, Noiseux NO, Hogue MH, Klaassen AL, Liu SS, Callaghan JJ (2016) Risk of acute kidney injury after primary and revision total hip arthroplasty and total knee arthroplasty using a multimodal approach to perioperative pain control including ketorolac and celecoxib. J Arthroplasty 31:253–255CrossRefGoogle Scholar